PartitionBio, a biotechnology company pioneering advanced biologics delivery technologies, today announced a strategic collaboration with Gene Weaver, an innovation-driven company specialising in programmable gene insertion. The agreement grants Gene Weaver an exclusive worldwide license to utilise PartitionBio's BubbleFect biologics delivery platform to deliver its proprietary gene insertion technology into mammalian cells.

Cambridge, UK, 07 May 2025 – Gene Weaver Ltd (Gene Weaver), a biology technology innovator, has received a grant from the Gates Foundation to support the development of a next generation gene insertion tool. The grant will support work on Gene Weaver’s gene editing platform, and its potential to enable a low-cost option for protein therapeutics in low- and middle-income countries (LMIC).